Short Communication

Effects of *Enterococcus* sp. isolated from deep seawater on inhibition of allergic responses in mice

Masatoshi Kondoh[1], Atsushi Hayashi[1], Mariko Okamori[1], Chie Motonaga[1], Tadao Enomoto[2], Lei Cheng[3] and Takashi Shimada[1,3]*

[1]*Central Research Laboratories, Nichinichi Pharmaceutical Corporation Ltd, 518-1417 Mie, Japan*
[2]*NPO Japan Health Promotion Supporting Network, 640-8269 Wakayama, Japan*
[3]*International Centre for Allergy Research, Nanjing Medical University, Nanjing, China & Sendai, Japan*

The objective of the present study was to assess the effects of *Enterococcus* sp. strain TN-3 isolated from deep seawater on inhibition of eosinophil accumulation, IgE production and active cutaneous anaphylaxis (ACA). We investigated the effects of viable and non-viable TN-3 on allergen-induced peritoneal eosinophil accumulation in mice. Viable (5.4×10^{10} colony-forming units per 60 mg) or non-viable TN-3 (60 mg) was orally administered to BALB/c mice that had been sensitised with the cedar pollen (*Cryptomeria japonica*) allergen. Oral administration of non-viable TN-3 was effective in suppressing eosinophil accumulation while viable TN-3 was ineffective. We also examined the dose–response relationship for non-viable TN-3 in regard to eosinophil accumulation, IgE production and ACA in allergen-primed mice. Non-viable TN-3 was orally administered at doses of 15 mg (low dose), 30 mg (medium dose) and 60 mg (high dose) to BALB/c mice that had been sensitised with cedar pollen allergen. The anti-allergic effects expressed as inhibition of eosinophil accumulation, IgE production and ACA were found at the low and high doses, but not at the medium dose. These results suggest that non-viable TN-3 exhibited anti-allergic effects at doses of 15 and 60 mg.

Allergy: Viability: Dose–response relationships: *Enterococcus* sp.

Most allergic diseases reflect an imbalance in lymphocyte-governed immunity, with immune responses to allergic molecules becoming overly biased toward T helper type 2 (Th2) cells. Secretion of cytokines such as IL-4, IL-5 and IL-13 by allergen-sensitised Th2 cells recruits granular effector cells such as eosinophils, basophils and mast cells to the site of allergic inflammation[1–3]. These effector cells, alone or in combination with cytophilic/reaginic IgE class antibodies, promote the clinical manifestations of allergy and atopy[4,5]. In addition, IL-4 and IL-13 promote B lymphocyte immunoglobulin isotype switching to IgE[6], and serve to increase circulating levels of total and allergen-specific IgE[7–10]. Significantly, it has been well documented that lactic acid bacteria (LAB) have the potential to modulate and regulate the immune response.

Most probiotic micro-organisms are classified as LAB, for example, *Lactobacillus* sp., *Bifidobacterium* sp. and *Enterococcus* sp.[11]. We have focused on *Enterococcus faecalis* strain FK-23. Heat-treated FK-23 possessed functionality expressed as anti-tumour and anti-microbial activities[12], immunomodulatory effects[13,14] and anti-hypertensive activity[15]. In addition, FK-23 processed by bacteriolytic enzyme- and heat-treatment exhibited anti-allergic activities[16–18].

We isolated *Enterococcus* sp. strain TN-3 from deep seawater in Toyama bay[19]. Physiological characterisation of TN-3 showed it to cause liquefaction of gelatin, fermentation-congelation of litmus milk and to possess β-galactosidase activity. TN-3 was identified as *E. faecium* using the API20strep kit (bioMérieux, Craponne, France), but had high homology to *E. durans* in respect of 16S rDNA nucleotide sequences. In the present study, we examined the anti-allergic effect of viable and non-viable TN-3 on allergen-induced peritoneal eosinophil accumulation in mice. Moreover, dose–response relationships were evaluated regarding the effect of non-viable TN-3 on eosinophil accumulation, active cutaneous anaphylaxis (ACA) and serum IgE production in allergen-primed mice.

Materials and methods

Preparation of viable and non-viable TN-3

TN-3 was cultured for 18 h at 30°C in a broth medium containing 2·46 % (w/v) glucose, 1·4 % (w/v) yeast extract,

---

Abbreviations: ACA, active cutaneous anaphylaxis; LAB, lactic acid bacteria.
* **Corresponding author:** Dr Takashi Shimada, fax +81 595 48 0209, email labo@nichinichi-phar.co.jp

0·77 % (w/v) peptone and 4·39 % (w/v) K_2HPO_4. After cultivation, the cells were collected by centrifugation, washed with distilled water and then lyophilised (viable TN-3). The number of live cells in this viable TN-3 powder was $9·0 \times 10^{11}$ colony-forming units/g. On the other hand, after washing, TN-3 was treated by autoclave for 10 min at 110°C and then lyophilised (non-viable TN-3).

Experimental animals

Female BALB/c mice were purchased from Charles River Japan Inc. (Yokohama, Japan). The mice, aged 5 weeks, used for experiments were fed on a pellet diet (CE-2; Clea Japan Inc., Tokyo, Japan) and received tap water that had been filtered through a PF filer (Organo Co., Tokyo, Japan). All animals were housed in cages with a 12 h light–dark cycle. The temperature and humidity were controlled at $25·0 \pm 1·0$°C and $55·0 \pm 5·0$%, respectively. The animal experimentation guidelines of our institute were followed. The experiments were performed in accordance with the guidelines for the care and use of experimental animals established by the Japanese Association for Laboratory Animals Science in 1987.

Administration of TN-3

Two main experiments were conducted. The first experiment was designed to determine the effects of TN-3 viability on anti-allergic properties. On day 0, the mice were divided into control (n 14), viable TN-3 (n 8) and non-viable TN-3 (n 8) groups. The mice of the control, viable TN-3 and non-viable TN-3 groups were administered saline (0·5 ml), viable TN-3 ($5·4 \times 10^{10}$ colony-forming units/60 mg per 0·5 ml) and non-viable TN-3 (60 mg per 0·5 ml) per mouse for 21 d, respectively.

The second experiment was designed to determine the dose–response effect of non-viable TN-3 on anti-allergic properties. On day 0, the mice were divided into control (n 7), low-dose (n 7), medium-dose (n 7) and high-dose (n 7) groups. The mice of the low-dose, medium-dose and high-dose groups were administered doses of 15 mg, 30 mg and 60 mg non-viable TN-3 per mouse for 21 d, respectively. The mice of the control group were administered 0·5 ml saline per mouse per d for the same duration.

Sensitisation of allergen

The animal model was prepared according to the procedure of Shimada et al. [16]. The mice were sensitised with the purified allergen extract (0·6 mg/ml) from Japanese cedar (Cryptomeria japonica) pollen[20]. For sensitisation, the allergen extract of 0·1 ml was injected subcutaneously on days 0 and 1, and then 0·2 ml was injected subcutaneously on days 6, 8 and 14.

Eosinophil accumulation

For challenge, the allergen extract (0·6 mg/ml) of 0·2 ml was injected intraperitoneally on day 20. After 24 h, mice were killed by carbon dioxide, and then peritoneal cells were collected with 4 ml PBS containing 1 % fetal calf serum and heparin (5 U/ml). The number of total leucocytes was counted with a haemocytometer under a microscope. A differential cell (eosinophils, neutrophils, monocytes and lymphocytes) count was carried out under a microscope after fixation and staining with May-Grunwald Giemsa dye. From these results, the proportion of eosinophils to total leucocytes was calculated.

Measurement of serum IgE

Following intraperitoneal challenge by the allergen extract (0·6 mg/ml) on day 20, blood samples of mice were collected 24 h after challenge. Total IgE and allergen-specific IgE in sera were measured by a sandwich ELISA according to the method of Shimada et al. [17]. For measurement of total IgE, ninety-six-well plates for ELISA were coated with each isotype-specific anti-mouse immunoglobulin antibody (PharMingen, San Diego, CA, USA) by incubation overnight at 4°C, and then further treated with 10 % (v/v) fetal calf serum added in PBS for 4 h at room temperature to block any non-specific binding. Subsequently, the serial dilutions of mouse serum samples were incubated in the well for 1 h at room temperature. Purified mouse IgE (PharMingen) antibody was used as the standard. After being washed three times in PBS containing 0·05 % (v/v) Tween 20, biotin-conjugated rat anti-mouse IgE (PharMingen) antibody was added to the well, followed by the addition of streptavidin-peroxidase (Zymed Laboratories, San Francisco, CA, USA) for 1 h at room temperature. After washing six times, the plates were developed using a tetramethylbenzidine substrate solution. The reactions were terminated by the addition of 0·33 M-phosphoric acid. The plates were read in a microplate reader (MTP-300; Corona Inc., Ibaragi, Japan) at 450 nm and the concentration of IgE was calculated according to the standard curve.

For determination of the serum levels of allergen-specific IgE, samples with the 2^{-2} and 2^{-4} dilutions were placed on ELISA plates coated previously with cedar pollen allergen. The experimental procedure then proceeded with the methods as described above, and the antibody levels were expressed as the absorbance at 450 nm.

Active cutaneous anaphylaxis

Following an intravenous injection of 0·05 ml Evans Blue (1 % (w/v); Sigma Chemical), ACA was elicited in the skin of the belly by the subcutaneous injection of 0·05 ml of cedar pollen allergen on day 21. At 30 min after the allergen challenge, mice were killed by carbon dioxide, and then a piece of skin shaved from each mouse was placed in 4·5 ml of mixture solution (1·5 ml sodium sulfate anhydrous (0·05 %, w/v) and 3·0 ml acetone). After vigorous shaking overnight, the absorbance of extravasated dye was measured colorimetrically at 620 nm.

Statistical analysis

The data are presented as the mean values and standard deviations. Statistical significance of the results was evaluated by Fisher's protected least significant difference (comparison between three groups) or the Bonferroni–Dunn test (comparison between four groups) using StatView software (SAS Institute, Inc., Cary, NC, USA). A value of $P < 0·05$ was considered significant.

Results

Effects of TN-3 viability on eosinophil accumulation

We first examined the anti-allergic effect with regard to the viability of TN-3 isolated from deep seawater on eosinophil accumulation. The total number of accumulated cells in the control, viable TN-3 and non-viable TN-3 groups was $1·15 \times 10^6$, $1·06 \times 10^6$ and $0·64 \times 10^6$ cells/ml, respectively. The number of cells was significantly lower in the non-viable TN-3 group than in the control group $(P<0·01)$. As shown in Fig. 1, the proportion of eosinophils to total leucocytes in the control, viable TN-3 and non-viable TN-3 groups was 21·5, 22·5 and 11·3 %, respectively. Non-viable TN-3 was found to significantly suppress the eosinophil accumulation in allergen-primed mice $(P<0·01)$. No significant difference was observed between the control and viable TN-3 groups.

Dose–response effect of non-viable TN-3 on eosinophil accumulation, IgE production and active cutaneous anaphylaxis

Table 1 shows the dose–response effect as to anti-allergic properties of non-viable TN-3 on eosinophil accumulation, IgE production and ACA. No signification difference was observed among all groups on the total number of accumulated cells. Mice that had been administered low (15 mg per mouse) and high (60 mg per mouse) doses of non-viable TN-3 had significantly suppressed eosinophil accumulation compared with control mice $(P<0·05)$. However, there were


Fig. 1. Effect of oral administration of viable or non-viable TN-3 on eosinophil accumulation in allergen-primed BALB/c mice. The mice were divided into control, viable TN-3 and non-viable TN-3 groups. The mice of the control, viable TN-3 and non-viable TN-3 groups were administered saline, viable TN-3 or non-viable TN-3 for 21 d, respectively. The mice were sensitised and challenged with the purified allergen extract from Japanese cedar (*Cryptomeria japonica*) pollen. Peritoneal cells were collected 24 h after challenge. The number of total leucocytes and differential cells (eosinophils, neutrophils, monocytes and lymphocytes) was counted, and from these results, the proportion of eosinophils to total leucocytes was calculated. Values are means, with standard deviations represented by vertical bars. ** Mean value was significantly different from that of the control group $(P<0·01)$.

no effects for eosinophil accumulation in the mice that had been administered the medium dose (30 mg per mouse).

Administration of non-viable TN-3 at low and high doses was found to significantly reduce the total IgE levels $(P<0·01)$. In contrast, total IgE in the medium-dose group had the same levels as the control group. No significant difference in the production of allergen-specific IgE was found between the three TN-3-administered groups and the control group.

Mice that had been administered low and high doses of non-viable TN-3 tended to have suppressed ACA compared with control mice $(P=0·107$ and $P=0·055$, respectively). On the other hand, no difference was observed in ACA between the medium-dose and control mice.

Discussion

In the present study, we demonstrated that non-viable TN-3, rather than the viable form, was effective in suppressing eosinophil accumulation in allergen-primed mice. Studies of the immunomodulatory properties of dietary LAB have drawn the general conclusion that live bacteria are more effective at modulating immunity than their non-viable counterparts[21]. However, the pro-Th1 immunomodulatory *Lactobacillus casei* and *L. plantarum* have been shown to down-regulate allergic molecules in antigen-primed mice either by oral delivery in the viable form or systemic delivery in the heat-killed form[22–26]. Differences in immunomodulatory properties as a function of LAB viability may depend on species and strains.

The health effects of non-viable probiotics have been summarised by Ouwehand & Salminen[27]. Thus it is clear that non-viable probiotics also have documented health effects. Some studies have also shown that effects on human health and well-being do not necessarily involve changes in the intestinal microflora or viability of the probiotic[27–29]. These studies have indicated that viability is not necessary for all probiotic effects, but further studies comparing viable strains and products with non-viable strains are urgently needed. In addition, studies involving not only heat-killed or otherwise inactivated microbes have shown that even the cell wall components of some probiotic microbes may have significant effects on the health and well-being of host animals when incorporated into the diet[30].

The use of non-viable instead of viable micro-organisms would have economic advantages in terms of longer shelf-life and reduced requirements for refrigerated storage. Non-viable micro-organisms expand the potential use of probiotics to areas where strict handling conditions cannot be met, for example, in developing countries. Safety is an important requirement for probiotics and it is worth noting that non-viable or inactivated microbial preparations have very few, if any, adverse effects. While there is a possibility of adverse reactions to the protein components of such preparations, adverse reactions have not been reported for currently used probiotics (viable, non-viable or cell wall components)[30]. Even though current probiotics are considered safe for food use[27,31], non-viable probiotics and microbial cell wall components are the least likely to cause safety concerns.

In the present study, non-viable TN-3 did not have the potential to inhibit eosinophil accumulation, IgE production

Table 1. Dose–response effect of non-viable TN-3 on eosinophil accumulation, IgE production and active cutaneous anaphylaxis (ACA)

(Mean values and standard deviations)

	Control		Low dose		Medium dose		High dose	
	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Eosinophil accumulation (%)	14·9	2·7	10·1*	2·3	14·1	4·0	10·6*	3·4
Total IgE (ng/ml)	4554	1372	2508**	828	3864	968	2467**	756
Allergen-specific IgE (absorbance at 450 nm)	0·262	0·099	0·200	0·154	0·178	0·097	0·274	0·121
ACA (absorbance at 620 nm)	0·450	0·112	0·367	0·082	0·454	0·100	0·346	0·047

Mean value was significantly different from that of the control group: * $P<0.05$, ** $P<0.01$.

and ACA in a dose-dependent manner at doses of 15, 30 and 60 mg. Interestingly, all three models of allergy gave the same results at the low and high doses, but not at the medium dose. Similarly, it has been reported that the effect of orally administered *L. casei* strain Shirota on total IgE production is not dose dependent[32]. It has been suggested that the amount of non-viable TN-3 used in the present study might constitute the optimal dosage for maximal inhibition of allergic responses. Further research is needed to elucidate the detailed mechanisms whereby orally delivered TN-3 exerts its anti-allergic effects, including evaluation of the optimal dosage.

References

1. Djukanović R, Wilson JW, Britten KM, *et al.* (1990) Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. *Am Rev Respir Dis* **142**, 863–871.
2. Hamelmann E & Gelfand EW (1999) Role of IL-5 in the development of allergen-induced airway hyperresponsiveness. *Int Arch Allergy Immunol* **120**, 8–16.
3. Leung DY (1995) Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. *J Allergy Clin Immunol* **96**, 302–318.
4. Durham SR (1998) Mechanisms of mucosal inflammation in the nose and lungs. *Clin Exp Allergy* **28**, Suppl. 2, 11–16.
5. Wills-Karp M (1999) Immunologic basis of antigen-induced airway hyperresponsiveness. *Annu Rev Immunol* **17**, 255–281.
6. Punnonen J, Aversa G, Cocks BG, *et al.* (1994) Role of interleukin-4 and interleukin-13 in synthesis of IgE and expression of CD23 by human B cells. *Allergy* **49**, 576–586.
7. Pene J, Rousset F, Briere F, *et al.* (1988) IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons γ and α and prostaglandin E$_2$. *Proc Natl Acad Sci U S A* **85**, 6880–6884.
8. Bochner BS, Undem BJ & Lichtenstein LM (1994) Immunological aspects of allergic asthma. *Annu Rev Immunol* **12**, 295–335.
9. Gajewski TF & Fitch FW (1988) Anti-proliferative effect of IFN-γ in immune regulation. I. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. *J Immunol* **140**, 4245–4252.
10. Brown MA & Hural J (1997) Functions of IL-4 and control of its expression. *Crit Rev Immunol* **17**, 1–32.
11. Klein G, Pack A, Bonaparte C, *et al.* (1998) Taxonomy and physiology of probiotic lactic acid bacteria. *Int J Food Microbiol* **41**, 103–125.
12. Abe S, Ohashi K, Uchida K, *et al.* (1993) Antitumor and anti-microbial activities of enterococcal preparation orally administered to mice. *Ann N Y Acad Sci* **685**, 372–374.
13. Hasegawa T, Ogura Y, Inomata T, *et al.* (1994) Effect of orally administered heat-killed *Enterococcus faecalis* FK-23 preparation on leukopenia in mice treated with cyclophosphamide. *J Vet Med Sci* **56**, 1203–1206.
14. Satonaka K, Ohashi K, Nohmi T, *et al.* (1996) Prophylactic effect of *Enterococcus faecalis* FK-23 preparation on experimental candidiasis in mice. *Microbiol Immunol* **40**, 217–222.
15. Shimada T, Kadowaki Y, Ohmiya K, *et al.* (1996) Identification of an RNA fraction from *Enterococcus faecalis* FK-23 cells as the antihypertensive compound. *J Ferment Bioeng* **82**, 109–112.
16. Shimada T, Cheng L, Ide M, *et al.* (2003) Effect of lysed *Enterococcus faecalis* FK-23 (LFK) on allergen-induced peritoneal accumulation of eosinophils in mice. *Clin Exp Allergy* **33**, 684–687.
17. Shimada T, Cheng L, Yamasaki A, *et al.* (2004) Effects of lysed *Enterococcus faecalis* FK-23 on allergen-induced serum antibody responses and active cutaneous anaphylaxis in mice. *Clin Exp Allergy* **34**, 1784–1788.
18. Shimada T, Cheng L, Enomoto T, *et al.* (2004) Lysed *Enterococcus faecalis* FK-23 oral administration reveals inverse association between tuberculin responses and clinical manifestations in perennial allergic rhinitis: a pilot study. *J Investig Allergol Clin Immunol* **14**, 187–192.
19. Hayashi A, Shimada T, Onaka H, *et al.* (2007) Isolation and phenotypic characterization of enterococci from the deep-sea-water samples collected in Toyama bay (article in Japanese with an English summary). *Jpn J Lactic Acid Bact* **18**, 58–64.
20. Yasueda H, Yui Y, Shimizu T, *et al.* (1983) Isolation and partial characterization of the major allergen from Japanese cedar (*Cryptomeria japonica*) pollen. *J Allergy Clin Immunol* **71**, 77–86.
21. De Simone C, Salvadori BB, Negri R, *et al.* (1986) The adjuvant effect of yogurt on production of γ-interferon by Con A-stimulated human peripheral blood lymphocytes. *Nutr Rep Int* **33**, 419–433.
22. Matsuzaki T & Chin J (2000) Modulating immune responses with probiotic bacteria. *Immunol Cell Biol* **78**, 67–73.
23. Kato I, Tanaka K & Yokokura T (1999) Lactic acid bacterium potently induces the production of interleukin-12 and interferon-γ by mouse splenocytes. *Int J Immunopharmacol* **21**, 121–131.
24. Tejada-Simon MV, Ustunol Z & Pestka JJ (1999) *Ex vivo* effects of lactobacilli, streptococci, and bifidobacteria ingestion

on cytokine and nitric oxide production in a murine model. *J Food Prot* **62**, 162–169.

25. Murosaki S, Yamamoto Y, Ito K, *et al.* (1998) Heat-killed *Lactobacillus plantarum* L-137 suppresses naturally fed antigen-specific IgE production by stimulation of IL-12 production in mice. *J Allergy Clin Immunol* **102**, 57–64.

26. Shida K, Makino K, Morishita A, *et al.* (1998) *Lactobacillus casei* inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures. *Int Arch Allergy Immunol* **115**, 278–287.

27. Ouwehand A & Salminen S (1998) The health effects of cultured milk products with viable and non-viable bacteria. *Int Dairy J* **8**, 749–758.

28. Salminen S, von Wright A, Morelli L, *et al.* (1998) Demonstration of safety of probiotics – a review. *Int J Food Microbiol* **44**, 93–106.

29. Saavedra JM (1995) Microbes to fight microbes: a not so novel approach to controlling diarrheal disease. *J Pediatr Gastroenterol Nutr* **21**, 125–129.

30. Salminen S & von Wright A (1998) Current human probiotics – safety assured? *Microbial Ecol Health Dis* **10**, 68–77.

31. Salminen S, Ouwehand A, Benno Y, *et al.* (1999) Probiotics: how should they be defined? *Trends Food Sci Tech* **10**, 107–110.

32. Matsuzaki T, Yamazaki R, Hashimoto S, *et al.* (1998) The effect of oral feeding of *Lactobacillus casei* strain Shirota on immunoglobulin E production in mice. *J Dairy Sci* **81**, 48–53.